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Abstract 
Variations in proton Relative Biological Effectiveness (RBE) with Linear Energy Transfer (LET) remain 
one of the largest sources of uncertainty in proton radiotherapy. This work seeks to identify metrics 
which can be applied to mitigate these effects in treatment optimisation, and quantify their 
effectiveness. Three different metrics – dose, dose × LET and an LET-weighted dose defined as 
𝐷𝑜𝑠𝑒 × (1 + 𝜅 𝐿𝐸𝑇𝐷) where 𝐿𝐸𝑇𝐷 is the dose-averaged LET, were compared with in vitro 
experimental studies of proton RBE and clinical treatment plans incorporating RBE models. In each 
system the biological effects of protons were plotted against these metrics to quantify the degree of 
variation introduced by unaccounted-for RBE uncertainties. As expected, the LET-dependence of RBE 
introduces significant variability in the biological effects of protons when plotted against dose alone. 
Plotting biological effects against dose × LET significantly over-estimated the impact of LET on cell 
survival, and typically produced even larger spreads in biological effect. LET-weighted dose was 
shown to have superior correlation to biological effect in both experimental data and clinical plans. 
For prostate and medulloblastoma treatment plans, the average RBE-associated variability in 
biological effect is ±5% of the prescribed dose, but is reduced to less than 1% using LET-weighting. 
While not a replacement for full RBE models, simplified metrics such as this LET-weighted dose can 
be used to account for the majority of variability which arises from the LET-dependence of RBE with 
reduced need for biological parameterisation. These metrics may be used to identify regions in 
normal tissues which may see unexpectedly high effects due to end-of-range elevations of RBE, or as 
part of a more general tool for biological optimisation in proton therapy.  
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Introduction 
Proton radiotherapy offers significant dosimetric advantages over conventional photon-based 
therapy, as protons’ continuous energy loss gives them a well-defined range with greatest energy 
deposition at the end of their path. As a result, normal tissues can be spared, reducing side-effects 
or allowing an escalation of target doses (Newhauser and Zhang 2015). 
However, the use of protons is not problem-free. Protons bring new challenges in dosimetry and 
planning, as variations in particle range with tissue composition can lead to classes of uncertainty 
not seen in photon radiotherapy (Paganetti 2012, Mohan et al 2017). But perhaps more importantly, 
there are also differences in biological effectiveness between photons and protons which are not 
typically incorporated in clinical planning. 
When different particles are used to deliver the same dose of ionising radiation, differences in 
biological effects are observed, typically defined in terms of a Relative Biological Effectiveness (RBE) 
– the ratio between the dose needed to produce a particular biological response with a reference 
radiation and the dose of a test radiation which produces the same effect. For protons, a constant 
RBE of 1.1 relative to photons is typically assumed, and plans are optimised based on physical dose 
alone (Paganetti 2014).  
While this reflects that protons are more biologically effective than photons, it assumes that this 
effect is a constant independent of dose, tissue type and LET, despite extensive preclinical evidence 
that proton RBEs are variable (Paganetti 2014). This reflects a significant limitation in proton 
treatment planning. By considering only the dose delivered, considerable uncertainty is introduced 
into the biological effect in each voxel due to variations in RBE, schematically illustrated in Figure 1a. 
While the introduction of a constant RBE factor can account for systematic changes in the average 
effect (Figure 1b), large variability can still exist on the level of individual voxels.  
The resulting uncertainties in biological effect are often larger than goals for physical uncertainty in 
treatment plans. As a result, proton therapy is not delivering on its full potential. Incorporation of 
the LET-dependence of proton RBE could reduce treatment uncertainties and potentially identify 
RBE ‘hotspots’ which may drive unexpectedly large responses, particularly at the end of range which 
typically occurs in normal tissue (Carabe et al 2012).  
Empirical analytic proton RBE models have been developed to better understand and quantify these 
effects. Typically, these models begin from the linear-quadratic cell survival model, and adjust the α 
and β parameters with the introduction of LET-dependent terms (Carabe-Fernandez et al 2007, 
Wedenberg et al 2013, McNamara et al 2015, Jones et al 2018). While accurate quantification of RBE 
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would offer the ideal method to account for these effects, these models have seen limited 
translation to the clinic. In part, this is because these models depend on both the α/β ratio of the 
target tissue as well as a number of model-specific fitting parameters which carry uncertainties and 
possible inter-patient variability, which translates into potentially large uncertainties in predicted 
RBE (Webb and Nahum 1993, Bentzen et al 1988, Paganetti 2017).  
However, for the purposes of treatment optimisation, full RBE models may not be required to 
mitigate these effects. It is important to note that even in photon-based therapy, treatments are 
planned based on physical dose rather than biological effect, and there considerable systematic 
uncertainty in the relationship between a given dose and the resulting level of biological effect – as a 
result of both inter-tissue and inter-patient variations in sensitivity (West et al 1993, Scheenstra et al 
2014, Alsbeih et al 2016). Despite this, dose-based planning is effective in photon therapy because 
no variation in biological response is expected between voxels in the same tissue exposed to 
different doses. Thus, by assuming tissue dose responses are monotonic – biological effects 
smoothly and continuously increase with dose – treatment plans can be efficiently optimised, even if 
the exact magnitude or functional dependence on dose is not known. 
A similar concept can be applied to proton therapy – even if there remains significant systematic 
uncertainties in RBE, metrics which combine physical parameters in a way which better correlates 
with response have the potential to serve as useful tools for treatment optimisation. The potential 
for this approach is highlighted by the observation that most commonly used RBE models are highly 
correlated in their predictions of RBE-weighted dose, suggesting a simpler metric which captures key 
aspects of the LET-RBE dependence may be able to provide most of the benefit of full RBE models 
for optimisation. This is conceptually illustrated in Figure 1c, showing an illustration of a metric 
which is nearly monotonically related with biological effect, substantially reducing biological 
variability at any given point even if it does not fully account for systematic differences in RBE.  
In this vein, groups have proposed optimisations based on the physical quantities of dose and LET as 
a proxy for response, rather than RBE models (Bassler et al 2010, Giantsoudi et al 2013, Wan Chan 
Tseung et al 2016, Unkelbach et al 2016). However, it remains unclear what metric is best suited to 
this purpose, or how effectively these simple metrics reduce biological variability in treatment 
planning. In this work, we evaluate dose, dose × LET and a weighted average of these quantities to 
evaluate their performance in reducing RBE-related variability as an alternative to ‘true’ RBE models. 
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Methods 
Biological Variability 
Considering dose alone is insufficient to predict the response of cells exposed to proton irradiation, 
due the LET-RBE relationship. In this work, we use the term ‘biological variability’ to describe the 
range of responses seen for a given dose. This can be quantified in terms of survival (as in Figure 2) 
or photon-equivalent RBE-weighted dose (Figures 4 & 6). For example, for the points illustrated in 
Figure 1, it can be seen that points exposed to a dose of 2 Gy can see effects equivalent to doses 
ranging from approximately 2 Gy to 2.6 Gy of photons, or a variability of ±0.3 Gy. It is important to 
note that this variability remains even when the average error in effect is corrected to zero via a 
constant RBE (as in Figure 1b), and can be reduced to effectively zero even when systematic 
uncertainty in the absolute value of RBE remains (as in Figure 1c).  
To quantify biological variability as in the clinical plans below, the variability at each dose was 
calculated as the size of the 95% confidence interval of biological responses seen at that dose in a 
given tissue. This was then averaged across the whole dose range to provide average uncertainties 
for different approaches.  
Radiation Response Metrics 
Three response metrics have been studied: physical dose, 𝐷; dose-LET product, 𝐷 × 𝐿𝐸𝑇𝐷 
(suggested by some authors as an RBE surrogate); and a weighted average of these metrics. This 
weighted average is given by 𝐷 + 𝜅 𝐷 ×  𝐿𝐸𝑇𝐷 = 𝐷 × (1 + 𝜅 𝐿𝐸𝑇𝐷), where 𝜅 is an empirical fitting 
parameter with units of μm/keV. This approach can potentially be applied to either track- or dose-
averaged LET. Track-average LET (𝐿𝐸𝑇𝑡) represents the simple arithmetic mean of the LETs of each 
individual particle in a field. However, this neglects the fact that a high-LET particle deposit 
proportionally more dose than a low-LET particle, which may lead to high-LET particles having a 
greater contribution to observed biological effect. To address this, the dose-averaged LET (𝐿𝐸𝑇𝐷) 
weights each particle’s LET by the dose it deposits in the target volume, and is chosen as the metric 
in this work (Guan et al 2015). 
As it is well established that the primary effect of radiation is an increase in the 𝛼 term of the LQ 
response curve, the LET-weighted dose metric is conceptually similar to the behaviour of 𝛼 in a 
number of RBE models, giving similar low-dose, low-LET trends (Carabe-Fernandez et al 2007, 
Wedenberg et al 2013, McNamara et al 2015). However, it includes only one parameter and 
deliberately does not attempt to convert to a tissue-specific biological effect or photon-equivalent 
dose, thus avoiding dependence on specific tissue biological parameters which are frequently poorly 
known. 
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Cell Survival Data 
Survival data for cells exposed to protons was obtained for AGO-1522 fibroblasts and U87 glioma 
cells from the literature (Chaudhary et al 2014, Marshall et al 2016). Clonogenic cell survival was 
measured at various positions across either pristine or spread-out Bragg peaks (SOBPs) to quantify 
the dose response curves at different energies, with doses from 0 to 7 Gy and 𝐿𝐸𝑇𝐷 from 1 to 25 
keV/μm. For each position, 𝐿𝐸𝑇𝐷 was calculated using Monte Carlo simulations of the beamline 
using Geant4 (Agostinelli et al 2003). Further details on experimental design can be found in the 
original papers (Chaudhary et al 2014, Marshall et al 2016). Although these studies used SOBPs 
generated in different fashions (passive scattering and pencil beam scanning, respectively), 
comparison of AGO-1522 dose responses from both papers found no significant difference in 
response at similar LETs, so these data were pooled and analysed as a single dataset. 
Survival from these experiments was plotted against each of the three candidate metrics. 
Correlation between each metric and biological response was assessed by fitting a function of the 
form ln(𝑆) = −𝐴𝑀 − 𝐵𝑀2, where 𝑀 is one of the three metrics, and 𝐴 and 𝐵 are fitting 
parameters.  
For 𝑀 = 𝐷, this reduces to the standard linear-quadratic dose response model with 𝐴 and 𝐵 taking 
units of Gy-1 and Gy-2. These units are also used for LET-weighted dose. For the 𝑀 = 𝐷 𝐿𝐸𝑇𝐷 case, A 
and B take units of μm keV-1 Gy-1 and um2 keV-2 Gy-2, respectively. While the dose-LET product can be 
rescaled to units of Gy by multiplying by a 𝜅-like term, this does not impact on the overall 
correlation.  
Spread Out Bragg Peak RBE Comparison 
Experimental data necessarily covers only a limited range of combinations of dose and 𝐿𝐸𝑇𝐷. To 
evaluate the metrics at a wider range of conditions and to better understand their underlying 
behaviour in this experimental dataset, RBE was modelled analytically across the whole SOBP. Dose 
and 𝐿𝐸𝑇𝐷 distributions were calculated for a 2 Gy SOBP delivered with 62 MeV protons with 10 mm 
range modulation by passive scattering, corresponding to that used experimentally (Chaudhary et al 
2014).  
At each point along the SOBP, RBE-weighted doses were calculated based on experimentally-
determined parameters. In this case, the explicit empirical RBE model used by Chaudhary et al in 
these publications was applied, which gave survival as: 
𝑆 = 𝑒−(𝛼𝑥+𝜆𝐿𝐸𝑇𝐷)𝐷−𝛽𝑥𝐷
2
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Where 𝛼𝑥 and 𝛽𝑥 are the experimentally-determined X-ray radiosensitivity parameters, and 𝜆 is an 
empirical fitting parameter describing the LET dependence of 𝛼 for protons (Chaudhary et al 2014, 
Marshall et al 2016). For these experiments, these parameters were determined to be: 𝛼 = 0.77 ±
0.02 Gy-1, 𝛽 = 0.06 ± 0.01 Gy-2 and 𝜆 = 0.06 ± 0.01 Gy-1 μm keV-1 for AGO-1522 cells; and 𝛼 =
0.13 ± 0.02 Gy-1, 𝛽 = 0.05 ± 0.02 Gy-2 and 𝜆 = 0.026 ± 0.003 Gy-1 μm keV-1 for U87 cells. These 
RBE-weighted doses were then plotted against each of the three metrics.  
Clinical Treatment Plan Comparison 
Finally, two clinical treatment plans were evaluated: one medulloblastoma and one prostate. 
Clinically delivered treatment plans were re-simulated using TOPAS (Perl et al 2012) as described 
elsewhere (McNamara et al 2015) to provide dose and 𝐿𝐸𝑇𝐷 distributions for the plans. Evaluation 
of these plans provided a test of these metrics in a clinically realistic distribution of doses and LETs. 
As specific survival data is not available for the tissues in these treatment plans, RBEs were 
calculated using a previously published phenomenological model (McNamara et al 2015). This model 
includes tissue α/β ratios and four empirical model parameters which were fit to published 
experimental data. RBE-weighted doses were then calculated for each plan, with α/β values set to 
10 Gy for the medulloblastoma, 1.5 Gy for the prostate. Normal tissue responses were modelled 
using an 𝛼/𝛽 of 3 Gy, as typically used when calculating risk of late effects. RBE-weighted doses 
were then compared to each of the three response metrics for all voxels seeing at least 1% of the 
prescription dose. 
Sensitivity Analysis 
A single value of 𝜅 was used throughout this work for all endpoints and cell types. This value was 
obtained by carrying out least-squares fitting to the experimental survival data in both cell lines as 
presented in Figure 2 c and f. In addition, only a single value of 𝛼/𝛽 was assumed for all normal 
tissue, to simplify the analysis of the correlation between LET- and RBE-weighted doses. 
To evaluate the sensitivity of the LET-weighted doses to 𝜅 and 𝛼/𝛽 ratio, we re-calculated the RBE-
weighted doses for the two treatment plans for normal tissue 𝛼/𝛽 ratios ranging from 2 to 10 Gy, 
corresponding to tissues with very fraction-size sensitive late effects to early responding, fraction-
size insensitive tissues. For each 𝛼/𝛽 ratio, we then calculated the average biological variability 
across the plans for 𝜅 ranging from 0 to 0.15. The resulting average variability, and total range, was 
then calculated as a function of 𝜅. 
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Results 
Cell Survival 
Experimental cell survival values are plotted against each of the response metrics in Figure 2 for 
AGO-1522 and U87 cells. Plotting against dose alone (a, d) shows the well-established LET 
dependence of proton RBE, with an average fit over-estimating cell killing at low LET and under-
estimating cell killing at high LET. This leads to a wide biological variability at all doses.  
When considering 𝐷 × 𝐿𝐸𝑇𝐷 (b, e), this trend is reversed, with the average fit under-estimating 
killing at low LET, and over-estimating at high LET, with a greater biological variability than seen for 
dose alone. This highlights that 𝐷 × 𝐿𝐸𝑇𝐷 alone is not a useful metric of biological response, but the 
trend is in line with suggestions that it is a proxy for additional biological effect, indicating that a 
combined metric may be useful. 
This combined LET-weighted dose, 𝐷 × (1 + 𝜅 𝐿𝐸𝑇𝐷), is plotted in the lower panels (c,f), with a 
fitted 𝜅 = 0.055 ± 0.003 μm/keV, showing significantly improved correlation. 𝑅2 values were 0.84 
and 0.88 for AGO-1522 and U87 cells when fit using dose alone, increasing to 0.99 and 0.95 when fit 
using LET-weighted dose (p<0.05, two-tailed Z-test of Fisher-transformed R values). Thus, applying 
LET-weighting with a single κ parameter thus accounts for 60 to 90% of the LET-related variability in 
survival in these cells. Notably, the use of this single parameter can be seen to be effective despite 
the different overall radiosensitivities and X-ray 𝛼/𝛽 ratios of these cell lines (12 Gy and 2.5 Gy), 
which necessitated the use of considerably different 𝜆 parameters in the original analysis. This 
highlights that by not trying to explicitly predict the magnitude of RBE, LET-weighting can more 
easily identify exposures with the same biological effect using only a single fitting parameter.  
Spread Out Bragg Peak RBE 
Figure 3 presents dose and 𝐿𝐸𝑇𝐷 distributions across a 2 Gy SOBP delivered using 62 MeV protons 
with a 10 mm range modulation, together with RBE-weighted doses for AGO-1522 and U87 cells 
using the published empirical model based on data in Figure 2. 
For each position along the depth-dose curve, RBE-weighted doses were compared to the different 
dose metrics, shown in Figure 4. Comparing dose alone to RBE-weighted dose shows similar trends 
to survival, under-estimating the effects of high LET exposures (a, d). In these plots, trends across the 
SOBP can be observed – initially, there is good correlation with dose in the low-LET entrance region 
(dark points) where RBE variations are small. But within the SOBP, dose is roughly constant while LET 
and RBE increase steeply. And then in the distal tail, dose falls steeply while RBE continues to 
increase, giving rise to a wide spread in possible biological effects at a given dose. 
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A similar variability is seen comparing with 𝐷 × 𝐿𝐸𝑇𝐷, although once again the trends with LET are 
reversed (b, e). An initially rapid rise is seen as dose increases, but within the SOBP the slope is much 
shallower, as the dependence of RBE-weighted dose on LET is much less than its dependence on 
physical dose. This also leads to a large over-estimation of effect in the distal tail.  
Applying the LET-weighted dose, again using 𝜅 = 0.055 μm/keV, substantially reduces this variability 
(c, f) as both physical dose and LET are appropriately taken into account. Improvements are seen in 
correlation in both cell lines despite the use of a single fitting parameter, with overall performance 
slightly better in AGO-1522 than in U87 cells. It is important to note that these plots show some 
curvature rather than the direct proportionality which would be expected of a ‘true’ RBE model, as 
LET-weighting deliberately does not seek to take into account differences in the underlying tissue 
biology and 𝛼/𝛽 ratio. However, by providing a monotonic correlation with biological effect, it can 
effectively identify regions of high cell killing for use in treatment design or optimisation. 
Clinical Treatment Plans  
Finally, these metrics have been studied in medulloblastoma and prostate clinical treatment plans, 
with dose and 𝐿𝐸𝑇𝐷 distributions shown in Figure 5. In common with most proton treatment plans, 
these approaches have relatively low LETs in the entrance region and much of the target volume, but 
higher LETs at the end of range and at edges of treatment fields. For each voxel in the treatment 
plan, an RBE-weighted dose has been calculated using the model of McNamara et al (McNamara et 
al 2015)  and compared against each of the three response metrics, plotted in Figure 6.  
Comparing dose alone (a, d) to RBE-weighted dose illustrates the range of biological variability in 
these plans if they are optimised on physical dose as is currently the case. There is considerable 
variation in biological effect across the whole dose range, equivalent to over ±5% of the prescription 
dose in both sites. This is again due to the lack of incorporation of RBE variability, with higher LET 
regions seeing increased biological effects. 𝐷 × 𝐿𝐸𝑇𝐷(b, e) is ineffective at resolving this issue, over-
estimating the impact of LET and introducing different biological uncertainties. 
However, the LET-weighted dose metric (c, f) greatly reduces this biological variability. By applying 
the same 𝜅 = 0.055 μm/keV as in the experimental dataset, the biological uncertainty in each plan 
is reduced to less than 1% across the whole dose range. This suggests that – despite taking a much 
simpler approach and fitting to only two reference cell lines – this approach effectively reproduces 
the trends seen in a significantly more complex RBE model fit to a comprehensive dataset.  
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Sensitivity analysis 
A single value of 𝜅 = 0.055 μm/keV has been used throughout this work, determined by minimising 
the biological uncertainties in an initial in vitro experimental dataset. To evaluate the applicability of 
this assumption, for each treatment plan the average biological uncertainty across the whole plan 
was calculated for different values of 𝜅 and 𝛼/𝛽, with the results illustrated in Figure 7.  
In the limit of 𝜅 = 0, this gives the biological variability when using dose alone, which as noted is 
approximately ±5% for a normal tissue α/β of 3 Gy as shown in Figure 6. This decreases as κ 
increases, reaching a minimum of less than 1% around 𝜅 = 0.055 μm/keV. This minimum is 
relatively shallow, with κ values from 0.04 to 0.08 all yielding average biological variabilities of less 
than 1.5%, suggesting that this metric still offers substantial improvements in predictive power even 
if the κ value is not precisely optimised.  
As the modelled RBE incorporates a dependence on 𝛼/𝛽, so too does the magnitude of the 
biological variability. A shaded range in Figure 7a shows the range of biological variation for 𝛼/𝛽 
ratios from 2 to 10 Gy for each 𝜅. This shows that both the maximum and minimum variability both 
initially fall with increasing 𝜅, with the worst-case error minimised around 𝜅 = 0.055 μm/keV.  
The 𝛼/𝛽 dependence is further illustrated in Figure 7b, which shows the average biological 
variability as a function of 𝛼/𝛽, for either physical dose alone or LET-weighted dose with 𝜅 = 0.055 
μm/keV. For high 𝛼/𝛽, corresponding to early-responding tissues and most tumours, both the total 
magnitude of the biological variability and the reduction obtained through LET-weighting are 
relatively small, due to the correspondingly small RBEs. For low 𝛼/𝛽 tissues, typically late-
responding normal tissues with greater fraction sensitivity, LET-weighting is much more effective, 
with 70-90% reductions in biological variability for tissues with 𝛼/𝛽 between 2 and 7 Gy 
(corresponding correlation plots in the style of Figure 6 are presented in the Supplementary 
Information). In absolute terms, the reduction in biological variability offered by LET-weighting 
increases monotonically as the 𝛼/𝛽 ratio falls. However, for very low 𝛼/𝛽 ratios corresponding to 
late-responding normal tissues and some tumours (e.g. prostate), the residual variability begins to 
increase as the initial variability rises more rapidly due to increasing RBE effects. 
While it is possible to offset this 𝛼/𝛽  dependence by specifically tuning 𝜅 for each 𝛼/𝛽 value, the 
magnitude of the improvement is relatively small (an average of 0.6%) and introduces parameters 
with significant additional uncertainty into the analysis. 
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Discussion 
Fully optimising treatment plans remains a significant challenge in radiotherapy, particularly in 
proton therapy where the LET dependence of biological response adds extra potential dimensions of 
optimisation (Underwood and Paganetti 2016). However, despite extensive evidence that proton 
RBE is variable, as seen in reviews of both preclinical datasets (Paganetti 2014) and published RBE 
models (Rørvik et al 2018), most clinical approaches adopt the conservative approach of a constant 
RBE of 1.1 (Mohan et al 2017). 
In this work, we explored the use of simplified metrics to reduce the biological variability in radiation 
response resulting from LET. In particular, we sought to identify metrics which were monotonically 
related to survival, without the need to explicitly calculate RBE values. By not attempting to generate 
equivalent photon doses, many aspects of the underlying biology which are subject to large 
uncertainties (such underlying tissue radiosensitivity and α/β parameters) can be neglected, greatly 
simplifying this calculation. The dose-LET product alone was found to not be a suitable approach, as 
it significantly over-estimates the impact of LET on cell killing and is not suitable for clinical 
application (as noted elsewhere (Jones 2017) ). However, despite its relative simplicity, we find that 
an LET-weighted dose substantially reduces variability in corresponding RBE-weighted doses 
predicted by a published RBE model (McNamara et al 2015) compared to dose alone. Similarly good 
performance is seen when LET-weighted doses are compared with other published models 
(Supplementary Information). 
This good performance across various RBE models is perhaps not surprising. Published LET-RBE 
models are highly correlated, typically agreeing on which regions see higher or lower RBEs even if 
they disagree on the exact magnitude of this effect. This points to common underlying assumptions 
about the relationship between RBE on LET, much of which is effectively captured by this LET-
weighted dose approach. Indeed, it is likely that the true underlying behaviour of cellular 
radiosensitivity actually depends on more complex variations in cellular energy deposition on the 
sub-cellular scale, which is necessarily only approximated by factors like LET (Hawkins 2003, Scholz 
and Elsässer 2007, McMahon et al 2017). As a result, it may be useful to also explore if other 
biophysical parameters which can be more directly measured, such as the dose-mean lineal energy 
(𝑦𝐷), may also provide useful correlations with biological effect (Tran et al 2017). 
These approaches have the potential to support planning in proton therapy. A major ongoing area of 
research is in optimising therapy to account for elevated end-of-range LETs in normal tissue which 
may lead to increased complication rates (Buchsbaum et al 2014). This metric can help guide such 
studies by identifying regions would be expected to show the greatest deviation from physical dose 
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alone. In addition, while optimising dose and LET independently may go some way to addressing RBE 
effects (Bassler et al 2010, Unkelbach et al 2016, Wan Chan Tseung et al 2016), because of the 
interplay between these parameters it is possible that reduction in physical dose will be offset by 
increases in LET, or vice-versa. By providing a metric which is monotonic in biological effect, 
optimisation of LET-weighted doses has the potential to offer more biologically robust solutions 
(Mohan et al 2017).  
It is important to note that this approach is not a true RBE model, and systematic differences 
between LET-weighted dose and RBE-weighted dose can be seen (Figures 4 & 6). For example, 
around 60 Gy in each treatment plan there is a systematic deviation on the order of 5% between 
LET-weighted and RBE-weighted dose. This increases at higher doses as the relationship between the 
two quantities is not perfectly linear. This effect arises because this approach does not attempt to 
take into account curvature of dose response and tissue-specific α/β values. This leads to differences 
in the curvature and scaling of the LET-weighted dose vs RBE-weighted dose relationship, with high 
𝛼/𝛽 tissues seeing shallower, straighter curves compared to low 𝛼/𝛽 tissues. This can be seen in 
Figure 6, where separate small clusters of points are seen at high doses, corresponding to tumour 
volumes with different α/β ratios to the normal tissue. This effect is also influenced by the 
dependence of RBE on the 𝛼/𝛽 of a given tissue, with high 𝛼/𝛽 tissues such as medulloblastoma 
being expected to see an RBE close to 1, while low 𝛼/𝛽 tissues such as prostate and late responding 
normal tissues would be expected to see much larger RBEs, meaning any RBE model must be applied 
with care. Further investigations which explore full RBE-weighted dose-volume effects in each target 
tissue with their individual radiosensitivity parameters will be necessary to confirm the wider 
applicability of this approach.  
As a result of these factors, this approach cannot be used to set the targets for optimisation such as 
delivered dose or dose-volume relationships, which will continue to have to be guided by clinical 
experience and data as at present. However, once these targets have been established, correlations 
between biological effect and LET-weighted dose remain good for any given tissue, enabling it to 
serve as a robust tool in planning optimisation even in the light of uncertainties in parameters such 
as the 𝛼/𝛽 ratio. As the exact shape of the relationship between biological effect and LET-weighted 
dose may remain uncertain for a particular cancer, it may also be advantageous to apply parameter-
independent plan comparison techniques when comparing different plans generated by this 
approach (Stavreva et al 2010). 
Finally, in this work, a value of 𝜅 = 0.055 μm/keV has been used based on a limited sample of in 
vitro experimental data. This is necessarily an approximation to the true underlying biology, and as 
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shown in Figure 7 leads to different degrees of residual biological variability in systems with different 
𝛼/𝛽 values, which may require caution if this model is to be applied to tissues such as CNS which 
may have particularly low 𝛼/𝛽 values at the limits of this approach’s tested range. While in principle 
𝜅 could be further refined to better approximate the underlying biology by introducing corrections 
for tissue 𝛼/𝛽 ratios or the dose and 𝐿𝐸𝑇𝐷 characteristics of the treatment plan, as shown in Figure 
6 and the Supplementary Information this relatively simple approach performs well compared to 
more sophisticated RBE models. This suggests that the benefits from the introduction of more 
complex variations of this metric would be relatively marginal.  
Before this approach can be translated into clinical practice, more comprehensive planning and 
analysis studies are needed to fully assess the performance of this model across the full range of 
clinical scenarios where it may be applied, quantifying the residual uncertainty when LET-weighted 
dose is applied. As an initial assessment, optimisation studies can be carried out comparing 
treatments optimised using LET-weighted dose to those generated using RBE models, to determine 
how effectively this simpler approach reproduces the full complexity of RBE models. In addition, if 
suitable data is available this approach can be used retrospectively to identify potential biological 
effect ‘hot-spots’ in clinical treatment plans, to determine if these correlate with observed toxicities. 
Such studies should include a detailed analyses which fully incorporates all features of the clinical 
problem for different sites (such as varying 𝛼/𝛽 ratios and normal tissue sensitivity for 
consequential late effects as seen in the CNS), and it is important to bear in mind that all RBE models 
considered here are based on cell survival endpoints which may not correspond directly to the RBE 
seen for dose-limiting late normal tissue toxicities. As a result, full validation of any RBE models is 
likely to require extensive, well-controlled clinical trials designed to provide greatest sensitivity to 
variations in treatment LET. 
Conclusions 
It has been shown that an LET-weighted dose metric, 𝐷 ×  (1 + 𝜅 𝐿𝐸𝑇𝐷), reduces biological 
variability resulting from changing RBE in proton therapy almost as effectively as full RBE models. 
While this cannot be used to set absolute dose constraints in general, it effectively identifies regions 
which may see elevated biological effects due to high LET, and may prove a valuable tool for therapy 
optimisation and retrospective response analysis without the need for the added complexity of full 
RBE models. 
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Figure 1: Schematic illustration of biological variability in RBE. A) RBE-weighted doses were 
generated for proton exposures to different doses and LETs (points, coloured by LET), with a 1:1 
correlation between metrics plotted as a dashed line. Unlike in photon therapy, dose does not 
uniquely map to biological effect, with LET-dependent variations in RBE give rise to a range of 
responses at a given dose. ‘Biological variability’ is here defined as the range of responses seen at a 
given dose, equivalent to the height of the shaded region. b) Use of a constant RBE can remove 
systematic RBE effects, giving zero net deviation to biological effect, but this does not impact on the 
biological variability. c) Through the use of an appropriate LET-weighted metric, it is possible to 
greatly reduce the variability in effect seen at any given LET-weighted dose. However, because this is 
not a full RBE model, some systematic deviation between model and biological effects may remain.  
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Figure 2: Variability in cell survival compared to different response metrics for AGO-1522 fibroblast 
(left) and U87 glioma (right) cells(Chaudhary et al 2014, Marshall et al 2016). Each point represents a 
single condition, coloured according to LET. When survival is plotted against dose (top), the LET-
dependence of proton RBE is seen, with increasing cell kill at higher LET. Plotting against 𝐷 × 𝐿𝐸𝑇𝐷 
(middle) sees greater biological variability, although with a reversed LET dependence. Plotting 
against LET-weighted dose (bottom), however, gives excellent correlation across all LETs, greatly 
reducing biological variability.  
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Figure 3: Dose and 𝐿𝐸𝑇𝐷 across 62 MeV SOBP with 10 mm modulation, along with RBE-weighted 
doses for two cell lines based on empirical fitting to data in Figure 2.  
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Figure 4: Correlation between RBE-weighted dose and response metrics across a SOBP in AGO-1522 
and U87 cells. Each point represents a 0.1 mm slice of the SOBP, coloured according to LET. For dose 
alone (top), there is a large biological uncertainty due to variations in LET, under-estimating effects 
in high LET regions. As in cell survival, this trend is reversed when considering 𝐷 × 𝐿𝐸𝑇𝐷 (middle), 
but the total biological variability is comparable. However, the LET weighted-dose metric (bottom) 
greatly reduces this variability in both cell lines.  
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Figure 5: Dose (top) and 𝐿𝐸𝑇𝐷 (bottom) distributions for prostate (left) and medulloblastoma (right) 
treatment plans. Tumour treatment volumes are outlined in white, while remaining volume is 
treated as uniform ‘normal tissue’ in this analysis. Each plan delivers a range of doses and LETs 
delivered using different beam geometries, and have been analysed to explore variations in RBE-
weighted dose with other metrics in realistic dose and LET distributions. 
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Figure 6: Comparison between McNamara RBE-weighted dose and metrics in clinical plans for 
prostate (left) and medulloblastoma (right). Point clouds have been plotted for each voxel receiving 
more than 1% of the prescription dose, coloured according to 𝐿𝐸𝑇𝐷. Dose alone (top) shows the 
biological variation inherent in clinical plans, with voxels assumed to see the same biological effect 
showing a variation equivalent to ±5% of the prescription dose, with high 𝐿𝐸𝑇𝐷 points seeing higher 
effects. 𝐷 × 𝐿𝐸𝑇𝐷 (middle) reverses this trend, but shows a much broader range of biological 
variability. LET-weighting (bottom) resolves much of this variability, with voxels of a given LET-
weighted dose having a very small spread in RBE-weighted dose.  
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Figure 7: Average biological variability in both treatment plans as a function of κ and 𝛼/𝛽. Left: 
Dependence on 𝜅. Points represent average response across 𝛼/𝛽 values from 2 to 10 Gy, while 
shaded region indicates full range. For 𝜅 = 0 this represents the uncertainty associated with using 
dose alone, and decreases to a minimum of approximately 1% around 𝜅 = 0.055 μm/keV. Right: 
Dependence of biological variability on 𝛼/𝛽 value for either physical dose, or LET-weighted dose 
with 𝜅 = 0.055 μm/keV. For all 𝛼/𝛽 ratios, LET-weighting with a single 𝜅 significantly reduces the 
biological variability.  
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